Mosnodenvir
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Mosnodenvir
- Molecular weight
- 582.98
- Structure (SMILES)
- COc1cc(N[C@H](C(=O)c2c[nH]c3ccc(OC(F)(F)F)cc23)c2ccc(Cl)cc2OC)cc(S(C)(=O)=O)c1
- jnj 1802
- jnj 64281802
- JNJ-1802
- Jnj-64281802
- JNJ-64281802
- mosnodenvir
- Mosnodenvir
- mosnodenvir [INN]
- MOSNODENVIR [USAN]
- Mosnodenvir [WHO-DD]
- mosnodenvir inn
- mosnodenvir usan
- mosnodenvir who dd
- CAS registry numbers
- 2043343-94-6
- ChEMBL ID
- CHEMBL5314530
- InChIKey
- QNOPDDHSGQQLCV-DEOSSOPVSA-N
- PubChem compound IDs
- 133083036
- FDA ingredient codes (UNII)
- 5EJO0RJF9O
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -denvir; -vir
- Condition
- Virus Diseases
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000763
- Subject identifier
- D014777
- Condition
- Severe Dengue
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004227
- Subject identifier
- D019595
- Condition
- Dengue
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005547
- Subject identifier
- D003715
- Condition identifier
- EFO_0000763
- Condition identifier
- EFO_0005547
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005108
- Condition identifier
- MONDO_0005502
- Highest recorded phase
- 2
- NCT04906980
- NCT05201794
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 2
- Polar surface area
- 106.72
- Calculated partition coefficient (ALogP)
- 6.18
- Calculated partition coefficient (XLogP)
- 6.1
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 9
- Heavy atoms
- 39
- Molecular formula
- C26H22ClF3N2O6S
- Monoisotopic mass
- 582.0839198
- Natural product
- No
- Recorded assays
- 65
- Active assays
- 11
Active assay types
- Confirmatory
These details could not be displayed.
Related records
Trials (4)
- A Study of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Challenge Model in Healthy Adult Participants
- A Study of JNJ-64281802 for the Prevention of Dengue Infection
- A Study of JNJ-64281802 in Healthy Adult Participants
- A Study of JNJ-64281802 in Participants With Confirmed Dengue Fever
In development for (3)
- Dengue disease Phase 2
- Dengue hemorrhagic fever Phase 2
- Viral infectious disease Phase 2